PostMenoGuide
For Educational Purpose Only
Gynaeguru
📖 Post-Menopause Clinical Overview
A comprehensive reference tool aligned with IMS 2024, NAMS 2023, BMS 2023 and ESHRE guidelines.
Definition & Diagnosis
WHO / IMS Criteria
Post-menopause is defined as the period beginning 12 consecutive months after the final menstrual period (FMP) in the absence of other physiological or pathological causes. Natural menopause occurs at a median age of 51 years.
Diagnostic Criteria
- Amenorrhoea ≥ 12 months (natural)
- FSH > 30–40 IU/L (confirmatory, age <45)
- Estradiol < 20 pmol/L
- Surgical: bilateral oophorectomy
- Iatrogenic: chemo/radiation-induced
- POI if < 40 years (distinct management)
Symptom Domains
- Vasomotor (hot flushes, night sweats)
- Urogenital atrophy (GSM)
- Psychological & cognitive changes
- Musculoskeletal (arthralgia, osteoporosis)
- Cardiovascular risk elevation
- Sexual dysfunction
- Metabolic changes (weight, glucose)
HRT Decision Tool
Interactive contraindication checker and personalised HRT selection guide based on NICE / NAMS protocols
→ Open Tool
Cardiovascular Risk Calculator
Estimate 10-year cardiovascular risk and estrogen timing hypothesis applicability (WHI / DOPS data)
→ Open Tool
Key International Guidelines
| Organisation | Guideline | Year | Key Stance |
|---|---|---|---|
| IMS | Menopause Hormone Therapy Recommendations | 2024 | MHT is first-line for VMS <60 or within 10 yrs of menopause |
| NAMS | Hormone Therapy Position Statement | 2022 | Benefits outweigh risks for most healthy women <60 |
| NICE | NG23 – Menopause Diagnosis & Management | 2023 update | Supports HRT; use transdermal to reduce VTE risk |
| BMS | Consensus Statement on HRT | 2020/2023 | Body-identical hormones preferred; annual review |
| ESHRE | Guideline on POI | 2024 | HRT mandatory in POI until age 51 |
| ESC | Cardiovascular Risk in Women | 2022 | Screen CVD risk at menopause; statin if indicated |
| IOF / NOF | Osteoporosis Clinical Guidelines | 2023 | DEXA at <65 if risk factors; HRT reduces fracture risk |
This tool is intended for healthcare professional use only. All clinical decisions should be individualised and reviewed against current local formularies and national guidance. This tool does not replace clinical judgement.
🌡️ Vasomotor Symptoms (VMS)
Hot flushes and night sweats affect 60–80% of post-menopausal women. Evidence-based classification and treatment hierarchy.
Symptom Classification
😐
Mild
< 7 flushes/day
No sleep disruption
Minimal interference
No sleep disruption
Minimal interference
😣
Moderate
7–10 flushes/day
Some sleep disruption
Affects daily activities
Some sleep disruption
Affects daily activities
😰
Severe
>10 flushes/day
Significant insomnia
Distressing, debilitating
Significant insomnia
Distressing, debilitating
Treatment Hierarchy (NAMS / IMS 2024)
First-Line – Lifestyle Modifications
Reduce room temperature
Layer clothing
Avoid triggers (alcohol, caffeine, spicy foods)
Regular aerobic exercise
Weight reduction if BMI >30
Mindfulness / CBT
Smoking cessation
Second-Line – Non-Hormonal Pharmacotherapy
| Drug | Dose | Reduction in Flushes | Notes |
|---|---|---|---|
| Fezolinetant (NK3R antagonist) | 45 mg/day | ~73% ★★★ | FDA/EMA approved 2023; first non-hormonal neurological agent |
| Venlafaxine (SNRI) | 75–150 mg/day | ~61% | First-choice SNRI; also treats depression/anxiety |
| Desvenlafaxine | 100–150 mg/day | ~55% | Fewer drug interactions than venlafaxine |
| Paroxetine CR (SSRI) | 7.5–12.5 mg/day | ~62% | Only FDA-approved SSRI for VMS (Brisdelle) |
| Escitalopram | 10–20 mg/day | ~47% | Good tolerability; evidence from MENQOL trial |
| Gabapentin | 300 mg TDS | ~45% | Useful if sleep disruption; monitor dizziness |
| Clonidine | 50–75 µg BD | ~25% | Modest effect; limited by hypotension |
| Oxybutynin | 2.5–5 mg/day | ~52% | Anticholinergic; recent RCT data (MsFLASH) |
Third-Line – Hormonal Therapy (see HRT Tool)
MHT / HRT remains the most effective treatment for VMS (80–90% reduction). Indicated when symptoms are moderate–severe and no contraindications exist. Refer to the HRT Decision Tool tab for personalised selection.
Complementary & Alternative Therapies ▾
Evidence is limited for most CAM therapies. Counsel patients about lack of regulatory oversight and potential interactions.
- Phytoestrogens (isoflavones, soy): Modest benefit (~20%); safe but variable bioavailability
- Black Cohosh (Cimicifuga): Some RCT evidence; avoid in liver disease; no estrogen activity confirmed
- Evening Primrose Oil: Insufficient evidence; widely used
- Acupuncture: Some trials show benefit; placebo effect likely; safe option
- Cognitive Behavioural Therapy (CBT): NICE-recommended; level 1A evidence for improving VMS perception and quality of life
- Hypnotherapy: Emerging evidence; reduces hot flush frequency by ~74% in some studies
- Stellate Ganglion Block: Invasive; reserved for cases refractory to all therapies
⚖️ HRT / MHT Decision Tool
Evidence-based contraindication screening and preparation selection — aligned with NICE NG23, NAMS 2022, IMS 2024, and BMS guidance.
Step 1 – Does the patient have any ABSOLUTE contraindications to systemic HRT?
Breast cancer (current/recent)
Endometrial cancer
Active VTE / PE
Unexplained vaginal bleeding
Active liver disease (severe)
Uncontrolled hypertension
Acute MI / CVA <6 months
HRT Preparation Selector
By route, indication, and progestogen requirement
| Route | Preparation | Estrogen | Progestogen | VTE Risk | Preferred In |
|---|---|---|---|---|---|
| Transdermal patch | Estradot, Evorel, FemSeven | 17β-estradiol 25–100 µg | Separate (Utrogestan/NETA) | 🟢 Lowest | VTE risk, older women, migraines |
| Transdermal gel | Oestrogel, Sandrena, Lenzetto | 17β-estradiol | Separate cyclic/continuous | 🟢 Lowest | Skin sensitivity; flexible dosing |
| Combined patch | Evorel Conti, Evorel Sequi | 17β-estradiol | NETA (continuous) | 🟡 Low | Intact uterus, post-menopause ≥12m |
| Oral tablet | Elleste, Kliovance, Prempak-C | 17β-estradiol / CEE | Norethisterone / MPA | 🔴 Higher | Mild symptoms; cost-sensitive |
| Vaginal (local) | Vagifem, Estriol cream, Imvexxy | Estradiol / Estriol | Not required | 🟢 Negligible | GSM only; breast cancer survivors (caution) |
| Intrauterine | Mirena IUS 52mg LNG | – (systemic E added separately) | Levonorgestrel | 🟢 Lowest | Endometrial protection; heavy periods |
| Implant (SC) | Estradiol 25/50/100 mg pellet | 17β-estradiol | Separate oral/IUS | 🟢 Low | Compliance issues; severe symptoms |
Body-identical hormones (micronised progesterone = Utrogestan; 17β-estradiol patches/gel) are preferred per BMS 2023 for their more favourable safety profile compared to synthetic progestogens.
Relative Contraindications – Individualise Decision
- Personal history of breast cancer (discuss benefits vs risks; local estrogen may be acceptable)
- BRCA1/2 mutation carriers (specialist referral)
- Endometriosis history (use continuous combined HRT)
- Fibroids (generally safe; monitor for growth)
- Gallbladder disease (use transdermal to avoid first-pass)
- Migraines with aura (transdermal preferred; oral contraindicated)
- Diabetes (safe; may improve glycaemic control)
- Hypertriglyceridaemia (avoid oral; use transdermal)
- Personal VTE history (transdermal; haematology review)
- Controlled hypertension (safe with transdermal; monitor BP)
❤️ Cardiovascular Risk & Post-Menopause
CVD is the leading cause of mortality in post-menopausal women. Estrogen deprivation accelerates atherosclerosis. The “timing hypothesis” is central to risk-benefit decisions.
10-Year CVD Risk Estimator
Based on QRISK3 / Framingham parameters
Estimated 10-Year CVD Risk
The “Timing / Window of Opportunity” Hypothesis
WHI re-analysis · DOPS trial · ELITE trial data
Key Principle: HRT initiated within 10 years of menopause or before age 60 is associated with reduced CVD risk. Initiation >10 years post-menopause in older women may be neutral or slightly harmful.
Evidence Supporting Timing
- ELITE Trial (2016): Estradiol reduced carotid intima-media thickness if started ≤6 years post-menopause; no benefit >10 years
- DOPS Trial (2012): CVD events reduced by ~52% in early initiators
- WHI Re-analysis: Estrogen alone reduced CHD in women aged 50–59
- NAMS 2022: Cardioprotective in younger post-menopausal women without established CVD
CVD Management in Post-Menopause
- Screen all women at menopause with fasting lipid profile, BP, glucose, BMI
- Mediterranean diet recommended (ESC 2022 – Grade IA)
- Statins if QRISK3 ≥10% – same as general population
- ACE inhibitors / ARBs for hypertension (avoid beta-blockers as first line)
- Aspirin NOT recommended for primary prevention post-menopause (USPSTF 2022)
- Address metabolic syndrome: waist >88 cm is high-risk criterion in women
Menopause-Specific CVD Risk Factors
| Risk Factor | Change at Menopause | Clinical Action |
|---|---|---|
| LDL Cholesterol | ↑ 10–15% | Fasting lipids annually; statin if QRISK3 ≥10% |
| HDL Cholesterol | ↓ 5–10% | Exercise; niacin if very low (<1.0 mmol/L) |
| Triglycerides | ↑ 10–20% | Dietary fat restriction; fibrates if >5.6 mmol/L |
| Blood Pressure | ↑ (loss of estrogen vasodilation) | Target <130/80 mmHg (ESC 2022) |
| Visceral adiposity | ↑ (android redistribution) | Waist ≤88 cm target; lifestyle; HRT reduces redistribution |
| Insulin resistance | ↑ (especially with weight gain) | Annual HbA1c or fasting glucose; GLP-1 agonists if obese |
| Arterial stiffness | ↑ (loss of estrogen effect) | Early HRT may attenuate progression |
| Atrial Fibrillation | ↑ prevalence >55 yrs | Annual pulse check; ECG if irregular |
🔬 Genitourinary Syndrome of Menopause (GSM)
GSM (formerly urogenital atrophy) affects 27–84% of post-menopausal women. Unlike VMS, it is progressive and does not resolve without treatment.
GSM – Symptom Domains
ISSWSH / AUGS 2022 consensus terminology
🌸 Vulvovaginal
Vaginal dryness, burning, irritation, dyspareunia, discharge changes, pH ≥5.0, loss of rugae
Vaginal dryness, burning, irritation, dyspareunia, discharge changes, pH ≥5.0, loss of rugae
🚷 Urinary
Urgency, frequency, nocturia, recurrent UTIs, stress incontinence, dysuria
Urgency, frequency, nocturia, recurrent UTIs, stress incontinence, dysuria
🔴 Sexual
Dyspareunia (primary symptom), reduced lubrication, decreased arousal, post-coital bleeding
Dyspareunia (primary symptom), reduced lubrication, decreased arousal, post-coital bleeding
Treatment Ladder (NAMS / ISSWSH 2023)
Step 1 – Non-Hormonal First-Line ▾
- Vaginal lubricants: Water-based (Replens MD, YES WB) for coitus; silicone-based (YES OB) longer-lasting; avoid petroleum-based with condoms
- Regular vaginal moisturisers: Hyaluronic acid gels (Hyalofemme), Replens – used 2–3×/week regardless of intercourse; comparable to topical estrogen at 12 weeks in mild cases
- Pelvic floor physiotherapy: Reduces dyspareunia and urinary urgency; refer to specialist physio
- Vaginal dilators: For significant stenosis or vaginismus
- Sexual activity: Regular intercourse/masturbation maintains vaginal blood flow and elasticity
Step 2 – Local (Topical) Estrogen Therapy ▾
Local vaginal estrogen is first-line pharmacotherapy for GSM. Systemic absorption is minimal and does not require progestogen addition.
Estradiol Vaginal Tablet (Vagifem 10 µg)
17β-Estradiol – Local
Dose: 1 tablet vaginally daily × 2 weeks, then twice weekly. Systemic levels remain postmenopausal. Safe in most breast cancer survivors (caution with AI users).
Estriol Vaginal Cream (Ovestin 0.1%)
Estriol – Local
Dose: 0.5 g (1 applicator) nightly × 3 weeks, then twice weekly. Estriol has weakest receptor affinity; preferred in breast cancer concern.
Estradiol Vaginal Ring (Estring 7.5 µg/day)
17β-Estradiol – Sustained Release
Inserted vaginally; releases 7.5 µg/day for 90 days. Good compliance; effective for atrophy and recurrent UTIs.
Prasterone / DHEA (Intrarosa 6.5 mg)
Intravaginal androgen – Converted locally to estrogen & androgen
Once-nightly vaginal suppository. FDA/EMA approved for dyspareunia. Minimal systemic absorption. Option for women unable to use estrogen.
Step 3 – Ospemifene (SERM) ▾
Ospemifene (Osphena) 60 mg oral daily
Selective Estrogen Receptor Modulator
Oral SERM with agonist activity on vaginal epithelium. Improves dryness and dyspareunia without vaginal application. Avoid if VTE history or endometrial cancer. Does not require progestogen. FDA/EMA approved for GSM.
Step 4 – Systemic HRT (if concurrent VMS) ▾
Systemic HRT addresses both VMS and GSM simultaneously. However, GSM may persist even on systemic therapy and may require addition of local vaginal estrogen. See HRT Decision Tool for preparation selection.
Recurrent UTI Management in Post-Menopause ▾
Post-menopausal women have 10× higher risk of recurrent UTI due to estrogen-deficient vaginal microbiome changes and urethral atrophy.
- Topical vaginal estrogen reduces recurrent UTIs by ~36% (Cochrane 2023)
- Cranberry prophylaxis: Limited evidence; 36 mg PAC/day for adherent patients
- Antibiotic prophylaxis: Post-coital or continuous low-dose (trimethoprim 100 mg nocte or nitrofurantoin 50–100 mg nocte) for ≥3 UTIs/year
- Methenamine hippurate (Hiprex) 1g BD – non-antibiotic alternative; evidence supports use in post-menopause
- Urology / urogynaecology referral if structural cause suspected
🦴 Bone Health & Osteoporosis
Women lose 2–3% of bone mineral density per year in the first 5–7 years post-menopause. Osteoporosis affects 30% of post-menopausal women over 50.
Screening & Diagnosis (IOF / NOF / NICE)
| Parameter | Normal | Osteopenia | Osteoporosis | Severe OP |
|---|---|---|---|---|
| T-score (DEXA) | ≥ −1.0 | −1.0 to −2.5 | ≤ −2.5 | ≤ −2.5 + fragility fracture |
| FRAX 10-yr hip fracture | < 3% | 3–5% | > 5% (treat) | Treat regardless |
| FRAX major osteoporotic | < 10% | 10–20% | > 20% (treat) | Treat regardless |
DEXA Screening Indications: Age ≥65 (all women); age <65 with risk factors (early menopause, low BMI, fracture history, long-term steroids, family history, smoking, excessive alcohol).
Pharmacological Treatment (NICE TA 160/161/204/464)
First-Line – Bisphosphonates ▾
Alendronic Acid 70 mg weekly
Bisphosphonate – Oral
Reduce vertebral fracture by 47%, hip fracture by 51%. Take fasting, 30 min before food/drink, remain upright. Contraindicated in renal impairment (eGFR <35). Review after 5 years; continue if high risk.
Risedronate 35 mg weekly / 150 mg monthly
Bisphosphonate – Oral
Alternative to alendronate; similar efficacy. Better tolerated in upper GI symptoms. eGFR threshold <30 for contraindication.
Zoledronic Acid 5 mg IV annually
Bisphosphonate – IV
Highest efficacy; hip fracture reduction 41%. Preferred if oral intolerance. Monitor calcium before infusion; flu-like reaction in 20% first dose. Duration 3–6 years then review.
Second-Line / High-Risk Options ▾
Denosumab 60 mg SC 6-monthly (Prolia)
RANK Ligand Inhibitor – Biological
No renal dose adjustment needed (preferred in CKD). FREEDOM trial: 68% vertebral fracture reduction. CRITICAL: Do not stop abruptly – transition to bisphosphonate to prevent rebound vertebral fractures.
Romosozumab 210 mg SC monthly × 12 months (Evenity)
Sclerostin Inhibitor – Anabolic
Dual action: builds bone AND reduces resorption. Use in severe osteoporosis or fracture despite bisphosphonate. Contraindicated in prior MI/stroke in last year. Follow with antiresorptive.
Teriparatide 20 µg SC daily (Forsteo) – 24 months
PTH Analogue – Anabolic
For severe osteoporosis or multiple fractures. Stimulates osteoblasts. Maximum 24-month course lifetime. Follow with bisphosphonate/denosumab. NICE criteria: T-score ≤ −4.0 or ≤−3.5 with ≥2 fractures.
Raloxifene 60 mg daily (SERM)
Selective Estrogen Receptor Modulator
Reduces vertebral fractures 30–50%; no proven hip fracture benefit. Bonus: reduces breast cancer risk 44%. Caution: increases hot flushes and VTE risk. Use in younger post-menopausal women with vertebral risk.
Universal Bone Health Measures (All patients)
- Calcium 1000–1200 mg/day (dietary preferred; supplement if inadequate)
- Vitamin D 800–1000 IU/day (target serum 25-OH-D >50 nmol/L)
- Weight-bearing exercise ≥30 min, 3×/week
- Balance training to reduce falls (OTAGO programme)
- Smoking cessation (reduces BMD and fracture healing)
- Alcohol <2 units/day
- Review medications causing bone loss (steroids, PPIs, anticonvulsants, aromatase inhibitors)
- Falls assessment + home hazard review in >70 years
🧠 Mental Health, Cognition & Sexual Health
Post-menopause is associated with increased vulnerability to depression, cognitive changes, and sexual dysfunction — all independently addressable.
Psychological Symptoms
Common Presentations
Low mood / depression
Anxiety / panic attacks
Irritability / rage
Brain fog
Memory difficulties
Poor concentration
Fatigue / apathy
Loss of confidence
Screening Tools
- PHQ-9 – depression severity (score ≥10 = moderate)
- GAD-7 – anxiety assessment
- Greene Climacteric Scale – menopause-specific psychological symptoms
- MoCA / MMSE – cognitive screening if concern
- MENQOL – menopause quality of life questionnaire
HRT can improve mood significantly in the peri/post-menopausal transition, particularly if low mood is estrogen-related. SSRIs/SNRIs are indicated for clinical depression regardless of HRT status. CBT (NICE NG23) is recommended for psychological symptoms at all severity levels.
Cognitive Health & Dementia Prevention
Women represent 65% of Alzheimer’s cases. Estrogen has neuroprotective effects. The critical window hypothesis applies to cognitive health similarly to cardiovascular risk.
HRT and Cognition – Evidence Summary ▾
- WHIMS (WHI Memory Study): Increased dementia risk with CEE+MPA in women >65 – likely due to late initiation
- Cache County Study: Early HRT (<5 years post-menopause) associated with reduced Alzheimer’s risk
- SWAN Study: Poor sleep during menopause transition predicts cognitive decline
- Current consensus (IMS 2024): HRT not recommended solely for cognitive protection; early initiation may be beneficial; avoid starting in women >60 with no other indication
- Prevention strategies: Physical exercise (≥150 min/week moderate aerobic) is the strongest evidence-based dementia prevention strategy
Sexual Health & Female Sexual Dysfunction (FSD)
ISSWSH / BASHH Guidance
| Disorder | Prevalence | First-Line Treatment | Pharmacotherapy |
|---|---|---|---|
| Hypoactive Sexual Desire Disorder (HSDD) | ~32% | Psychosexual therapy, relationship counselling | Testosterone off-label (BSSM 2019); Bremelanotide (USA) |
| Genito-Pelvic Pain / Penetration Disorder | ~30% | Pelvic floor physio, dilators, lubricants | Local estrogen, Prasterone, Ospemifene |
| Female Sexual Arousal Disorder | ~17% | Psychosexual therapy; treat GSM if present | PDE5 inhibitors (limited evidence); local estrogen |
| Orgasmic Disorder | ~25% | Vibrator devices; CBT-sex therapy | Testosterone (off-label) |
Testosterone Therapy (BSSM / IMS 2019): Off-label transdermal testosterone (e.g. Testogel 1% gel at female physiological doses ~0.5 g/day) is supported by evidence for HSDD in post-menopausal women. Monitor total testosterone levels; target pre-menopausal range. Review every 6 months.
Sleep Disorders in Post-Menopause
- Prevalence: 39–47% of post-menopausal women report clinically significant insomnia
- Causes: Night sweats, sleep apnoea (3× higher post-menopause), anxiety, pain
- CBT for Insomnia (CBT-I): Gold standard – NICE recommended; includes sleep restriction, stimulus control, relaxation
- HRT: Significantly improves sleep quality by reducing night sweats
- Gabapentin 300 mg nocte: Dual action on VMS and sleep onset
- Melatonin 0.5–5 mg: Evidence for sleep onset; limited long-term data in post-menopause
- Orexin receptor antagonists (Lemborexant, Suvorexant): Licensed for insomnia; limited menopause-specific data
- Obstructive sleep apnoea screening: STOP-BANG questionnaire; refer for polysomnography if >3 symptoms
💊 Drug Reference Guide
Complete pharmacological reference for post-menopausal management — dosing, safety, monitoring, and contraindications.
Systemic Estrogen Preparations
17β-Estradiol Patch (Evorel, Estradot, FemSeven)
Systemic Estrogen – Transdermal
Doses: 25, 37.5, 50, 75, 100 µg/24h · Change: Twice weekly or weekly · Monitoring: BP, symptom review at 3 months then annually · Key benefit: Avoids first-pass hepatic metabolism → lowest VTE risk of systemic preparations · Counselling: Apply below waistline; rotate sites; avoid sunbeds on patch
Estradiol Gel (Oestrogel 0.06%, Sandrena)
Systemic Estrogen – Transdermal Gel
Dose: 0.5–3 pumps/sachets daily (1–3 mg estradiol) · Apply to: Inner thigh, arm, or abdomen · Allow to dry: 5 minutes before dressing · Notes: Dose flexibility; alcohol hand-wash after; partner/child transfer risk if contact within drying period
Conjugated Equine Estrogen – CEE (Premarin 0.3–1.25 mg)
Systemic Estrogen – Oral
Dose: 0.3–0.625 mg/day usually sufficient · Use: When body-identical not preferred or cost limitations · Caution: Higher VTE risk vs transdermal; more hepatic protein stimulation · Monitoring: Annual BP, breast examination
Progestogen Preparations
Micronised Progesterone (Utrogestan 100/200 mg)
Body-Identical Progestogen – Oral / Vaginal
Cyclic: 200 mg nocte days 1–12 of each month (sequential HRT) · Continuous: 100 mg nocte daily (post-menopausal >1 year) · Key advantage: Neutral on breast cancer risk vs synthetic progestogens (E3N study); sedative effect aids sleep; no androgenic side effects · Nut allergy: Contains peanut oil – use with caution
Norethisterone Acetate (NETA – Primolut-N, in Evorel Conti)
Synthetic Progestogen – Oral / Patch
Dose: 0.5–1 mg/day continuously or 1 mg/day cyclically · Combined patches: Evorel Sequi, Evorel Conti · Notes: Androgenic; may cause acne, bloating; higher breast cancer signal than micronised progesterone
Levonorgestrel IUS (Mirena 52 mg)
Intrauterine Progestogen
Duration: 8 years (off-label for endometrial protection for 5 years per NICE) · Benefit: Virtually no systemic progestogen effects; excellent endometrial protection; also treats menorrhagia · Note: Requires gynaecological insertion; not licensed specifically for HRT endometrial protection but widely used (BMS endorsed)
SERMs & Other Hormonal Agents
Tibolone 2.5 mg daily (Livial)
Synthetic Steroid – Estrogenic / Progestogenic / Androgenic
Indications: VMS, GSM, bone protection, libido · Use: Post-menopausal women >12 months amenorrhoea only (not peri-menopausal) · Advantages: Single daily tablet; improves libido and energy; reduces breast density · Caution: Increased stroke risk in women >60 (LIFT trial); breast cancer risk similar to combined HRT; avoid in women with prior breast cancer
Bazedoxifene + CEE (Duavive)
Tissue-Selective Estrogen Complex (TSEC)
Dose: 0.45 mg CEE / 20 mg BZA once daily · Unique feature: Provides endometrial protection without progestogen via SERM component · Indication: VMS in post-menopausal women with intact uterus who wish to avoid progestogen · Caution: VTE risk; not for breast cancer history
Novel & Emerging Agents
Fezolinetant (Veoza) 45 mg daily
NK3 Receptor Antagonist – Non-Hormonal
MOA: Blocks neurokinin B signalling in the hypothalamic KNDy neurons responsible for thermoregulation · Efficacy: Reduces moderate-severe flush frequency by ~73% at 12 weeks (SKYLIGHT trials) · Approval: FDA May 2023, EMA Feb 2024 · Monitoring: LFTs at baseline, 3 and 6 months · Contraindicated in: Cirrhosis, CYP1A2 inhibitors (fluvoxamine, ciprofloxacin)
Elinzanetant – NK3R Antagonist (Phase III)
NK3 Receptor Antagonist – Investigational
OASIS trials showed significant VMS reduction + improved sleep. NDA submitted 2024. If approved, will offer twice-daily alternative to fezolinetant.
Testosterone Transdermal (Off-label – Androfeme, Testogel)
Androgen – Female Physiological Dose
Indication: HSDD (BMS/BSSM/IMS endorsed; not licensed in this indication) · Dose: Testogel 1% – 0.5 g/day to inner thigh · Target level: Free testosterone within pre-menopausal reference range · Monitoring: Total and free testosterone, SHBG at 3 and 6 months · Safety: No cardiovascular or breast cancer risk at physiological doses
Drug Interactions – Key Alerts
| HRT Component | Interacting Drug | Effect | Action |
|---|---|---|---|
| Oral estrogen | CYP3A4 inducers (rifampicin, carbamazepine, St John’s Wort) | ↓ Estrogen levels → reduced efficacy | Use higher dose or switch to transdermal |
| Oral estrogen | Warfarin | ↑ or ↓ INR variably | Monitor INR closely; consider transdermal |
| Paroxetine (VMS) | Tamoxifen | ↓ Active tamoxifen metabolite → reduced breast cancer protection | Use alternative SSRI/SNRI |
| Fezolinetant | Fluvoxamine, ciprofloxacin | ↑ Fezolinetant levels (CYP1A2 inhibition) → hepatotoxicity risk | Contraindicated – do not co-prescribe |
| Raloxifene | Warfarin, cholestyramine | ↓ Warfarin effect; ↓ raloxifene absorption | Monitor INR; separate dosing by 2h |
| Tibolone | Anticoagulants | May affect coagulation parameters | Monitor; avoid in thromboembolic disease |
📋 Follow-Up, Monitoring & Preventive Care
Structured annual review aligned with NICE NG23, BMS, and RCGP recommendations for post-menopausal women on and off HRT.
Annual Review Checklist – HRT Users
Symptoms & Wellbeing
- VMS control (frequency, severity) – use validated tool (MRS/MENQOL)
- Mood, sleep, cognitive function, libido
- Urogenital symptoms (GSM assessment)
- Review HRT formulation, dose, route, compliance
- Side effects: bloating, breast tenderness, spotting
- New contraindications? (cancer diagnosis, VTE, MI)
Clinical Examination & Tests
- Blood pressure measurement
- BMI / waist circumference
- Breast examination (if clinically indicated)
- Pelvic examination if postmenopausal bleeding
- Fasting lipids, glucose / HbA1c (if risk factors)
- Mammography per national programme (UK: 50–71 yrs 3-yrly)
Preventive Screening Schedule (Post-Menopause)
| Screening | Interval | Population | Notes |
|---|---|---|---|
| Mammography | Every 3 years | All women 50–71 (UK NHS) | Annual if family history / BRCA / dense breasts |
| Cervical smear / HPV | Every 5 years | Up to age 65 (UK) | Post-menopausal dryness may require moisturiser before smear |
| DEXA (bone density) | At menopause then 2–5 yrs | Women with risk factors; ≥65 all | Use FRAX to determine treatment threshold |
| Cardiovascular risk | Annual | All post-menopausal women | QRISK3; lipids, BP, glucose, BMI |
| Colorectal cancer | Every 2 years | 50–75 years (FIT test) | Colonoscopy if FIT positive; HRT reduces CRC risk (observational) |
| Thyroid function (TSH) | Every 5 years or if symptomatic | Symptomatic / family history | Hypothyroidism mimics menopause symptoms |
| Pelvic USS | If symptomatic only | Postmenopausal bleeding | Endometrial thickness >4 mm warrants biopsy |
| Skin cancer | Annual if high risk | Personal/family history; sun exposure | Skin changes can be estrogen-related; refer if uncertain |
Red Flags – When to Refer / Investigate Urgently
Urgent Referral (2WW) Required:
- Unexplained postmenopausal bleeding (any bleeding >12m amenorrhoea)
- Breast lump or new nipple discharge
- New-onset pelvic mass on examination
- Haematuria (exclude bladder/renal malignancy)
- Unintentional weight loss >5% body weight
Stop HRT & Review Urgently:
- DVT or PE symptoms (calf pain, SOB, pleuritic chest pain)
- New diagnosis of breast, endometrial, or ovarian cancer
- Acute liver disease or jaundice
- MI, stroke, or TIA
- Sudden severe headache (migraine with new aura on oral HRT)
HRT Duration – Evidence & Guidance
NICE NG23 (2023): There is no arbitrary time limit on HRT duration. The decision to continue should be based on individual benefit-risk assessment at each annual review. Discontinuation is not recommended at age 50 or after 5 years if benefits outweigh risks.
How to stop HRT – Tapering Strategy ▾
- Gradual dose reduction preferred over abrupt cessation to minimise rebound VMS
- Reduce patch dose or gel pumps by 50% for 3 months; then 25% for further 3 months
- If VMS recur on reduction: maintain dose; attempt taper again after 6–12 months
- Some women will require HRT long-term – this is acceptable if annual review supports continuation
- Offer non-hormonal alternatives (fezolinetant, venlafaxine) at cessation if VMS persist
Lifestyle Medicine in Post-Menopause ▾
- Mediterranean diet: Reduces CVD, cancer, cognitive decline; decreases VMS frequency in observational studies
- Aerobic exercise 150 min/week: Reduces VMS, improves mood, prevents bone loss, reduces CVD risk
- Resistance training 2×/week: Preserves muscle mass; prevents sarcopenia (↑ risk post-menopause)
- Alcohol: <14 units/week; avoid bingeing; alcohol worsens VMS and breast cancer risk
- Smoking cessation: Reduces VMS; reduces CVD/cancer risk; use NRT / varenicline
- Sleep hygiene: Consistent wake time, dark/cool room, no screens 1h before bed
- Stress management: Mindfulness, yoga, and paced respiration (4-7-8 technique) reduce hot flush perception
- Social connectedness: Strong social network associated with better menopausal outcomes (WHI observational)